Prelude's CEO, Dr. Kris Vaddi, asserts that the additional f...

Moomoo AI Dec 11, 2023 22:37

Prelude's CEO, Dr. Kris Vaddi, asserts that the additional funding will boost the clinical development of PRT3789 and progress of the oral program. Further clinical results from PRT3789 and the initiation of their oral program are expected in second half of 2024.

Press Release: Prelude Therapeutics Announces $25 Million Private Placement

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

5393 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4641Followers

0Following

10KVisitors